Engineered immune cells take aim at tough T-Cell cancers
NCT ID NCT07070323
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of CAR T-cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells or cells from a donor, which are modified in a lab to attack the cancer. The trial has two phases: the first checks safety and the best dose, and the second looks at how well it works in 54 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD5 CAR T-cells (made from the patient's own cells or a donor's cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with hard-to-treat T-cell cancers who have run out of standard therapies.
- What could go wrong
- This is an early phase 1/2 trial with only 54 participants, so results are preliminary. CAR T-cell therapy can cause severe side effects like cytokine release syndrome and nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
-
Shanghai Liquan Hospital
RECRUITINGShanghai, Shanghai Municipality, 201418, China
-
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITINGChengdu, Sichuan, 610083, China
-
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
RECRUITINGShanghai, Shanghai Municipality, 200435, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we make CAR-T cells last longer in leukemia?
- Engineered immune cells take aim at tough childhood leukemia
- Selective immune cell removal may tame transplant complications
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New drug combo tested for tough childhood leukemia
- Promising CAR-T therapy for tough blood cancers hits snag – study withdrawn